Tumor News and Research

RSS

SRI and Taiho collaborate to advance clinical development of TAS-108 breast cancer program

SRI International, an independent nonprofit research and development organization, announced today that it has assumed responsibility for further clinical development of the TAS-108 breast cancer program, in cooperation with Taiho Pharmaceuticals Co., Ltd., a leading Japanese pharmaceutical company. Further clinical development will focus on the lead compound's registration for the treatment of tamoxifen and aromatase inhibitor-resistant breast cancers.

20 Aug 2010

Muscle mass plays key role in cancer survival: Research

In the vast majority of patients with advanced cancer, their muscles will gradually waste away for reasons that have never been well understood. Now, researchers reporting in the August 20 issue of Cell, a Cell Press Publication, have found some new clues and a way to reverse that process in mice. What's more, animals with cancer that received the experimental treatment lived significantly longer, even as their tumors continued to grow.

20 Aug 2010

Second round of abstract submission for International Symposium on MR-guided Focused Ultrasound

Due to overwhelming response from researchers, a second round of abstract submissions for the upcoming 2nd International Symposium on MR-guided Focused Ultrasound will open on Monday, August 23, 2010, nine days earlier than previously announced. The submission deadline will be moved forward to Monday, September 6, 2010.

19 Aug 2010

Siemens Healthcare to distribute Calypso GPS System in Europe

Calypso Medical Technologies, Inc., a developer of real-time localization technology used for the precise tracking of tumor targets, today announced that it has entered into a non-exclusive product distribution agreement with Siemens Healthcare for the sale of its Calypso® System in Europe. Under terms of the agreement, Siemens retains non-exclusive rights to sell Calypso's real-time tracking technology to existing and prospective Siemens linear accelerator customers throughout Europe for a period of three years.

19 Aug 2010

China PharmaHub and Chengdu Yongkon Pharmacy sign cooperation agreement

China PharmaHub Corp., recently merged with World Wide Relics, which will be shortly changing its name to China PharmaHub Corp, is proud to announce it has signed a cooperation agreement with Chengdu Yongkon Pharmacy Co. Ltd., a pharmaceutical company based in Sichuan, with an established sales network of over 2600 hospitals in China.

18 Aug 2010

XOMA sells royalty interest in CIMZIA

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced today that it has sold its royalty interest in CIMZIA® (certolizumab pegol) marketed by UCB S.A. for $4 million to an undisclosed buyer. The manufacture of CIMZIA is covered by a license to XOMA's Bacterial Cell Expression technology.

18 Aug 2010

Varian to showcase new Gated RapidArc technology at 2010 CHINA-HOSPEQ exhibition

Varian Medical Systems, Inc. will showcase the company's new Gated RapidArc technology on its Trilogy® machine with advanced motion management capabilities at the 2010 CHINA-HOSPEQ exhibition being held in Beijing August 19-21 by China's Ministry of Health. Varian, the world's leading manufacturer of medical technology for treating cancer and a premier supplier of X-ray imaging technology, will also exhibit its software for planning and for managing radiation therapy treatments.

18 Aug 2010

Study shows increase in IL-6 secretion can reduce Tarceva sensitivity to treat lung tumor cells

One of the most tantalizing developments in anti-cancer therapy over recent years has been the advent of targeted treatments, which have proven highly effective in holding aggressive cancers at bay in certain patients, although typically only for a limited period of time.

18 Aug 2010

Adult stem cells associated with poor prognosis of cancer: Research

Adult stem cells that are vital for airway repair in the lung but that persist in areas where pre-cancerous lesions are found are associated with a poor prognosis in patients who develop cancer, even those with early stage disease, researchers at UCLA's Jonsson Comprehensive Cancer Center have found.These adult stem cells are found in repairing areas after injury and also are found in pre-cancerous areas, suggesting that these cells may mutate and become cancer causing stem cells, making them a potential cell-of-origin for lung cancer and a possible target for prevention strategies and new targeted therapies.

18 Aug 2010

ImmunoCellular Therapeutics raises $6.5 million in second quarter 2010

ImmunoCellular Therapeutics today announced second quarter results for the period ended June 30, 2010. The Company utilized $1.13 million of cash in its operations during the quarter. The increase in net burn is reflective of increased personnel costs as well as increase in Research and Development costs associated with the planned phase II clinical trial for ICT-107.

18 Aug 2010

Merck's SIMPONI anti-TNF therapy now reimbursed in New Brunswick, Nova Scotia and Alberta

Merck is pleased to announce that New Brunswick, Nova Scotia and Alberta are the first provinces in Canada to reimburse SIMPONI(golimumab) for the treatment of three different rheumatic conditions. SIMPONI, a subcutaneous anti-tumor necrosis factor therapy, is now reimbursed by the drug formularies of these three provinces for people living with moderately to severely active rheumatoid arthritis, moderately to severely active psoriatic arthritis and active ankylosing spondylitis.

17 Aug 2010

Chronix Biomedical expands biomarker development capabilities with installation of DNA mass sequencer

Chronix Biomedical today reported that it has significantly expanded and accelerated its biomarker development capabilities with the installation of Germany's first state-of-the-art high-throughput DNA mass sequencer at the University of Göttingen, Chronix's long-time collaborator. Chronix is developing disease-specific biomarkers based on DNA fragments that are released into the bloodstream by damaged and dying (apoptotic) cells.

17 Aug 2010

Nanoparticle-based gene silencing system inhibits angiogenesis process in tumor growth

A protein associated with cancer progression when abundant inside of tumors also unexpectedly regulates the creation of new blood vessels that feed the tumor outside, a research team led by scientists at The University of Texas MD Anderson Cancer Center reports in the August edition of Cancer Cell.

17 Aug 2010

Scientists identify possible therapeutic strategy for reducing leukemia risk from chemotherapy

A UCSF-led team has discovered at least one key reason why blood stem cells are susceptible to developing the genetic mutations that can lead to adult leukemia. Their finding also may explain, they say, why some other age-related hematological disorders develop.The study, reported in "Cell Stem Cell" and reviewed in Cell Stem Cell and Cell, opens a new frontier for studying the molecular underpinnings of adult leukemia.

17 Aug 2010

AACR invites application for carcinoid and pancreatic neuroendocrine tumor research grant

The American Association for Cancer Research is pleased to announce new grant-giving partnerships with the Caring for Carcinoid Foundation (CFCF) and the Raymond and Beverly Sackler Fund for the Arts and Sciences.

17 Aug 2010

Researchers find link between chronic inflammation and cancer

Virginia Commonwealth University Massey Cancer Center researchers have uncovered a new link between chronic inflammation and cancer. Although cancers do not always cause inflammation, chronic inflammation is known to help tumor cells grow.

17 Aug 2010

NanoSmart receives USPTO Notice of Allowance for cancer tumor targeting technology

NanoSmart™ Pharmaceuticals, Inc., a California corporation developing novel biopharmaceuticals, is pleased to report that it has received a Notice of Allowance for a US patent on its proprietary cancer tumor targeting technology.

16 Aug 2010

Enrollment open in Phase I clinical study of Morphotek's MORAb-028 for advanced melanoma

Morphotek, Inc., a subsidiary of Eisai Inc., announced today that the John Wayne Cancer Institute in Santa Monica, California has opened enrollment in a Phase I clinical study with MORAb-028 in patients with advanced melanoma.

16 Aug 2010

Pathology experts meet to at SESPM to update new advances in breast surgery

Over 1.500 breast pathology experts will meet between the 20th and 22nd of October in the 16th World Congress of the Senologic International Society (SIS). This meeting and the 29th Congress of the Spanish Society of Senology and Breast Diseases (SESPM) will take place in the Valencia, coinciding with the International Breast Cancer Day.

16 Aug 2010

Medicare disability recipient dies of brain tumor after having coverage interrupted

Milwaukee Journal Sentinel: "Paula Oertel, whose brain tumor disappeared for nine years while she was on an expensive drug and returned after she temporarily lost her insurance coverage, has died as a result of the tumor spreading through her brain. The interruption of her Medicare coverage of the drug directly contributed to her death, contends her doctor, Mark Malkin, chief of neuro-oncology at Froedtert Hospital.

16 Aug 2010

Tumor News and Research

SRI and Taiho collaborate to advance clinical development of TAS-108 breast cancer program

Muscle mass plays key role in cancer survival: Research

Second round of abstract submission for International Symposium on MR-guided Focused Ultrasound

Siemens Healthcare to distribute Calypso GPS System in Europe

China PharmaHub and Chengdu Yongkon Pharmacy sign cooperation agreement

XOMA sells royalty interest in CIMZIA

Varian to showcase new Gated RapidArc technology at 2010 CHINA-HOSPEQ exhibition

Study shows increase in IL-6 secretion can reduce Tarceva sensitivity to treat lung tumor cells

Adult stem cells associated with poor prognosis of cancer: Research

ImmunoCellular Therapeutics raises $6.5 million in second quarter 2010

Merck's SIMPONI anti-TNF therapy now reimbursed in New Brunswick, Nova Scotia and Alberta

Chronix Biomedical expands biomarker development capabilities with installation of DNA mass sequencer

Nanoparticle-based gene silencing system inhibits angiogenesis process in tumor growth

Scientists identify possible therapeutic strategy for reducing leukemia risk from chemotherapy

AACR invites application for carcinoid and pancreatic neuroendocrine tumor research grant

Researchers find link between chronic inflammation and cancer

NanoSmart receives USPTO Notice of Allowance for cancer tumor targeting technology

Enrollment open in Phase I clinical study of Morphotek's MORAb-028 for advanced melanoma

Pathology experts meet to at SESPM to update new advances in breast surgery

Medicare disability recipient dies of brain tumor after having coverage interrupted

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News